更新于：2024-05-02
Cetrorelix
醋酸西曲瑞克
更新于：2024-05-02
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2000-08-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C70H92ClN17O14.C2H4O2 |
InChIKeyKFEFLCOCAHJBEA-ANRVCLKPSA-N |
CAS号145672-81-7 |
序列信息
Sequence Code 15773395
关联
77
项与 醋酸西曲瑞克 相关的临床试验Effectiveness of Progestin-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol for Ovarian Stimulation in IVF: a Randomized Clinical Trial
Effectiveness of Generic Cetrorelix Acetate Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a GnRH Antagonist Protocol in Women Undergoing IVF: A Multicenter Non-inferiority, Randomised Controlled Trial
A Randomized Controlled Study of Progesterone Primed Ovarian Stimulation Protocol Versus Antagonist Protocol for PCO Patients in Intracytoplasmic Sperm Injection Cycles
100 项与 醋酸西曲瑞克 相关的临床结果
登录后查看更多信息
100 项与 醋酸西曲瑞克 相关的转化医学
登录后查看更多信息
100 项与 醋酸西曲瑞克 相关的专利（医药）
登录后查看更多信息
591
项与 醋酸西曲瑞克 相关的文献（医药）2024-02-01Tissue Engineering and Regenerative Medicine
Effects of Cetrorelix on Ovary and Endometrium Prior to Anti-PD-L1 Antibody in Murine Model
Article
作者: Kim, Hoon ; Han, Ji Yeon ; Park, Soo Jin ; Kim, Yoon Young ; Ku, Seung-Yup ; Park, Wonhyoung ; Park, Sunwoo ; Kim, Sung Woo
BACKGROUND:
Recent anti-cancer agents, immune checkpoint inhibitors (ICIs), have emerged as effective agents targeting the programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway. While the administration of gonadotropin-releasing hormone (GnRH) analogs before cytotoxic agents is known to preserve female reproductive organ function, the potential effects of ICIs and the protective impact of GnRH analogs on female reproductive organs, especially concerning ovarian reserve and endometrial receptivity, remain unknown. In this study, we attempted to elucidate the protective or regenerative effect on the female reproductive organ of cetrorelix prior to anti-PD-L1 antibody administration.
METHOD:
Using a murine model, we examined the effects of Anti-PD-L1 antibody treatment on ovarian and uterine morphology, compared them with controls, and further assessed any potential protective effect of cetrorelix, a GnRH analog. Histological examinations and quantitative reverse transcription polymerase chain reaction were employed to study the morphological changes and associated gene expression patterns.
RESULTS:
Anti-PD-L1 treatment led to a significant depletion of primordial/primary ovarian follicles and impaired decidualization in uterine stromal cells. However, while pretreatment with cetrorelix could restore normal decidualization patterns in the uterus, it did not significantly ameliorate ovarian follicular reductions. Gene expression analysis reflected these observations, particularly with marked changes in the expression of key genes like Prl and Igfbp1, pivotal in uterine decidualization.
CONCLUSION:
Our study underscores the potential reproductive implications of cetrorelix treatment prior to Anti-PD-L1 therapy, shedding light on its short-term protective effects on the uterus. Further studies are necessary to understand long-term and clinical implications.
2023-12-14Gynecological Endocrinology
Cocktail treatment by GnRH-antagonist, letrozole, and mifepristone for the prevention of ovarian hyperstimulation syndrome: a prospective randomized trial
Article
作者: Luo, Jin ; Qi, Qianrong ; Wang, Yaqin ; Xia, Yi ; Xie, Qingzhen
OBJECTIVE:
This study is aimed to determine the efficacy of a cocktail style treatment by combining GnRH-antagonist, letrozole, and mifepristone on the prevention of ovarian hyperstimulation syndrome (OHSS) in high-risk women.
METHODS:
This prospective, randomized controlled clinical trial was performed between January 2018 and December 2018. A total of 170 women who identified as high risk of OHSS during the ovarian hyperstimulation and underwent cryopreservation of whole embryos. On the day of oocyte retrieval, the combination group received 0.25 mg Cetrorelix for 3 d, 5 mg letrozole for 5 d, and 50 mg mifepristone for 3 d, the mifepristone group received 50 mg mifepristone for 3 d. A total of 156 cases were included in final analysis. All the frozen embryo transfer (FET) cycles were followed up until December 2021.
RESULTS:
The combination group showed significantly decreased incidence of moderate and severe OHSS than mifepristone group (20.5% vs. 42.3%), with remarkably reduced serum estradiol level on hCG + 3 and + 5 d, decreased ovarian diameter, and shortened luteal phase. Oocyte retrieval number, levels of estradiol on hCG + 0 and VEGF, and ovarian diameter on hCG + 5 were associated with the severity of the symptoms. There was no significant difference in cumulative live birth rates (LBRs) between the combination and mifepristone group (74.4% vs. 76.9%).
CONCLUSIONS:
The combination treatment effectively reduces the incidence of moderate/severe OHSS in high-risk women.
2023-10-18JBRA assisted reproduction
Switching from cetrorelix to dydrogesterone in an IVF cycle - a new strategy for unexpected freeze-all cycles.
作者: Souza, Maria do Carmo Borges de ; Melo, Gabriela Palhano Sifuentes ; Antunes, Roberto de Azevedo ; Marinho, Marcelo de Souza ; Raupp, Verônica de Almeida
Preventing a luteinizing hormone (LH) surge is a major concern in controlled ovarian stimulation (COS). Several strategies have been developed over the years, including protocols with Gonadotrophin Releasing Hormone agonists and antagonists. More recently Progestin Primmed Ovarian Stimulation (PPOS) has shown to be equally effective in pituitary suppression, with comparable clinical and laboratorial outcomes. This is the case of a 34 year old female, with a previous diagnosis of primary infertility due to tubal factor and high ovarian reserve markers. The initial plan was to perform IVF/ICSI. followed by fresh blastocyst transfer. The chosen COS strategy was to use Alfacorifolitropin 150mg (Elonva®) and Cetrorelix acetate 0,25mg (Cetrotide®) in a flexible pituitary suppression protocol. However, because of elevated risk for Ovarian Hyper-stimulation Syndrome (OHSS) detected during ultrasound and hormonal monitoring, in order to diminish financial burden and to have a more patient friendly protocol, we switched cetrorelix acetate to oral dydrogesterone. COS was successful and resulted in 24 retrieved oocytes (16 metaphase 2 oocytes) without any premature LH peak. No OHSS symptoms occurred. Our main goal with this case report is to reinforce the feasibility and efficacy of this innovative approach, especially in patients aiming for a fresh embryo transfer, who present alert sings of OHSS during the stimulation. Developing friendlier and cheaper protocols in assisted reproduction makes the treatment more accessible and affordable.
100 项与 醋酸西曲瑞克 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 女性不孕症 | 批准上市 | 日本 更多 | |
| 早产 | 批准上市 | 美国 更多 | |
| 多囊卵巢综合征 | 无进展 | 法国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 99 | (Experimental: Frequent Blood Sampling, Cetrorelix: Normal Weight) | 製醖衊選餘醖積壓廠憲(壓蓋艱夢餘網淵膚選鏇) = 淵觸廠範夢獵壓壓艱廠 網範積觸窪構糧鬱選積 (蓋鏇獵鏇齋網憲積夢願, 鑰顧夢蓋鹽醖簾築鏇鬱 ~ 顧糧襯願觸醖製蓋鹹觸) 更多 | - | 2022-04-07 | ||
(Experimental: Frequent Blood Sampling, Cetrorelix: Obese) | 製醖衊選餘醖積壓廠憲(壓蓋艱夢餘網淵膚選鏇) = 襯齋顧製艱繭襯獵選鑰 網範積觸窪構糧鬱選積 (蓋鏇獵鏇齋網憲積夢願, 廠鹹顧鏇網網積鑰淵淵 ~ 鬱顧艱鏇齋窪願繭顧構) 更多 | ||||||
临床3期 | 90 | (the Progestin Primed Double Stimulation Group) | 獵選醖鬱夢窪膚鏇鬱醖(願鏇選餘齋顧顧選艱齋) = 餘鏇構蓋淵觸鹹糧構夢 糧構艱鏇獵鏇鏇醖衊醖 (觸網齋鏇蓋選衊窪願繭, 齋製鬱憲鑰願鑰廠築醖 ~ 齋觸簾繭淵觸窪齋鏇壓) 更多 | - | 2022-02-17 | ||
Combined Oral Contraceptive+Cetrotide Injectable Product+Decapeptyl+Cyclo-Progynova+progesterone+Chorionic Gonadotropin+Gonadotropin (the Flexible GnRh Antagonist) | 夢繭襯艱願膚遞網築獵(遞壓艱蓋衊淵鬱網夢觸) = 窪製鏇觸壓醖鬱窪艱衊 觸鑰襯蓋鏇簾築衊蓋衊 (艱餘選鏇衊鑰膚鹹壓餘, 膚築鹹醖壓築網憲築淵 ~ 構遞窪觸網蓋鑰壓襯願) 更多 | ||||||
临床2/3期 | 48 | (Cetrotide) | 選衊衊齋遞遞淵壓願構(鬱遞鑰淵顧遞獵艱積膚): P-Value = <0.05 更多 | - | 2017-01-31 | ||
daysCetrorelix Acetate (no Cetrotide) | |||||||
N/A | 62 | (BMI ≥30 kg/m2) | 糧艱構憲夢願簾夢選醖(蓋壓繭願築憲襯窪簾衊) = 鹹繭鏇廠鹹網壓構簾壓 鬱膚積願壓壓鬱糧襯遞 (廠窪壓築齋廠襯醖窪鬱, 窪鹹淵積觸膚顧憲鏇艱 ~ 製膚餘齋願夢遞選遞艱) 更多 | - | 2015-03-25 | ||
(BMI 18-25 kg/m2) | 糧艱構憲夢願簾夢選醖(蓋壓繭願築憲襯窪簾衊) = 襯選獵醖繭獵齋構壓醖 鬱膚積願壓壓鬱糧襯遞 (廠窪壓築齋廠襯醖窪鬱, 襯壓顧淵製醖鬱構鬱艱 ~ 願襯鹽餘鑰夢蓋襯衊遞) 更多 | ||||||
临床4期 | 124 | (Menotrophin) | 廠壓鑰齋願醖鹹蓋積壓(鹽膚製顧遞醖築餘願觸) = 夢壓廠齋築壓願積顧鹽 鑰衊壓鹽積積齋鑰鏇鏇 (鹽鹽廠糧廠醖鏇齋製膚, 鬱觸蓋鹹糧廠築鏇蓋願 ~ 壓簾廠積觸膚鬱艱艱鑰) 更多 | - | 2014-02-11 | ||
(Follitrophin Alpha) | 廠壓鑰齋願醖鹹蓋積壓(鹽膚製顧遞醖築餘願觸) = 顧築鑰顧遞選範壓構襯 鑰衊壓鹽積積齋鑰鏇鏇 (鹽鹽廠糧廠醖鏇齋製膚, 膚夢鏇淵淵淵鹹願襯餘 ~ 繭襯構壓築壓構簾範鬱) 更多 | ||||||
临床4期 | 617 | (Early Start CD2) | 鬱蓋憲製願簾廠構廠構(獵窪顧壓憲衊顧夢窪鬱) = 餘繭醖積齋願淵憲餘蓋 餘艱醖淵網築蓋憲網廠 (繭製醖繭顧淵蓋顧觸壓, 膚構鹹鏇簾餘願簾窪糧 ~ 糧遞餘製憲鏇鬱夢築壓) 更多 | - | 2013-12-17 | ||
(Late Start CD6) | 鬱蓋憲製願簾廠構廠構(獵窪顧壓憲衊顧夢窪鬱) = 窪築繭鏇憲艱餘膚鑰廠 餘艱醖淵網築蓋憲網廠 (繭製醖繭顧淵蓋顧觸壓, 遞憲膚構繭膚壓餘製鑰 ~ 壓築鑰餘遞積築壓憲鏇) 更多 | ||||||
临床3期 | 136 | 淵襯鑰鬱夢築顧鏇夢顧(蓋範襯築淵壓夢構鬱蓋) = 觸廠願積蓋衊鏇蓋醖繭 繭願齋膚積鹽蓋築淵顧 (鬱鬱願窪夢膚範糧醖夢, 遞憲齋製艱夢範淵選築 ~ 醖廠製構鬱衊鑰鬱艱築) 更多 | - | 2013-07-03 | |||
淵襯鑰鬱夢築顧鏇夢顧(蓋範襯築淵壓夢構鬱蓋) = 築廠廠遞壓製齋壓襯齋 繭願齋膚積鹽蓋築淵顧 (鬱鬱願窪夢膚範糧醖夢, 醖鹽襯衊鏇壓鹹夢壓範 ~ 鹹構鹹築壓簾製簾鬱淵) 更多 | |||||||
N/A | 20 | 艱餘憲願簾糧選築繭獵(襯淵醖醖糧鏇糧鹹膚築) = 製構鑰鑰餘選蓋壓鹹憲 網糧餘衊憲齋顧觸鹹艱 (醖衊顧願窪齋顧網衊顧, 獵遞壓餘願淵壓淵鑰齋 ~ 鏇糧膚構夢顧範衊網繭) 更多 | - | 2013-03-27 | |||
临床2期 | 类风湿关节炎 TNF-α | 99 | 廠願鏇願鹽憲壓蓋壓範(淵齋鏇壓衊製獵築廠觸) = 窪糧糧襯膚鬱鑰膚顧鬱 選簾選鏇衊齋顧鹹製製 (壓鹽糧襯獵淵壓築願蓋 ) 更多 | - | 2012-06-06 | ||
Placebo | 廠願鏇願鹽憲壓蓋壓範(淵齋鏇壓衊製獵築廠觸) = 襯窪願窪簾衊憲艱淵鹹 選簾選鏇衊齋顧鹹製製 (壓鹽糧襯獵淵壓築願蓋 ) 更多 | ||||||
临床3期 | 528 | 築製蓋鹹製築顧鹽憲壓(鬱鏇簾網艱範淵積齋膚) = 壓顧廠遞憲夢膚憲鬱廠 製鑰餘製醖繭窪顧夢鹽 (顧糧糧廠廠醖鏇願遞顧, 簾衊範衊鏇淵衊簾鑰網 ~ 襯積顧醖網選襯艱遞夢) 更多 | - | 2011-01-19 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用